Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy
Sponsor: Peking University Cancer Hospital & Institute
Summary
In this project, based on the DTPA-HAS kit, investigators plan to develop a positron nuclide 68Ga labeled DTPA-HSA molecular probe in order to obtain high sensitivity, signal-to-noise ratio and high-resolution PET/CT imaging images, aiming to find the specific site of intestinal leakage while diagnosing Protein-Losing Enteropathy (PLE), and analyze the pathological mechanism of intestinal leakage in combination with pathology, so as to provide molecular imaging guidance for the treatment of PLE patients. PLE is a rare gastrointestinal protein-losing syndrome, and the radiopharmaceutical 99mTc-DTPA-HSA (99mTc-human serum albumin) approved by the State Food and Drug Administration has the diagnostic ability of protein-losing enteropathy (PLE), but due to the low resolution of SPECT/CT, the image clarity and signal-to-noise ratio need to be improved, it is a classic probe in the last century, unable to meet the existing clinical needs.
Official title: Development and Clinical Translation of Protein-losing Enteropathy (PLE) Imaging PET Probe
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-05-01
Completion Date
2026-05-31
Last Updated
2024-12-04
Healthy Volunteers
No
Conditions
Interventions
68Ga-HSA
68Ga-HSA PET/CT: after intravenous injection of 2.22 MBq/kg body weight of quality-controlled 68Ga-HSA, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Locations (1)
Beijing Cancer Hospital
Beijing, Beijing Municipality, China